Difference between revisions of "Sertraline-maprotiline"

From Psychiatrienet
Jump to: navigation, search
 
(One intermediate revision by one other user not shown)
Line 3: Line 3:
 
| to = maprotiline  
 
| to = maprotiline  
 
| stop =  
 
| stop =  
* '''Before day 1:''' gradually reduce dosage of sertraline to a maximum of 50 mg/day when this dosage is > 50 mg/day.
+
{{TCAdecrease25p3d}}
* '''Day 1:''' reduce dosage of sertraline to a maximum of 25 mg/day.
 
 
| start =  
 
| start =  
Caution is necessary.
+
{{TCAincrease25p3d}}
* '''Day 1:''' simultaneously start administration of maprotiline in a low dosage of 25 mg/day.
+
| info =
* '''Day 8:''' stop administration of sertraline and only continue administration of maprotiline in a dosage of 50 mg/day.
+
{{TCAplasmalevelmonitoring}}
* "Start low, go slow" is not required, but caution is necessary.
+
}}
| info =  
 
* Sertraline dose-dependently slows the metabolism of maprotiline via CYP2D6.
 
{{review}} }}
 

Latest revision as of 13:15, 30 June 2023

Sertraline
Type Antidepressant
Group SSRI
links
Medscape Sertraline
PubChem 68617
PubMed Sertraline
Kompas (Dutch) Sertraline
Wikipedia Sertraline
Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline

Switch medication from sertraline to maprotiline.[1] [2]

Nietinrijdenbord.png Stop sertraline
  • Day 1: Decrease with about 25% of the original dose per 3 days.
Eenrichtingbord.png Start maprotiline
  • Day 1: Increase with about 25% of target dose per 3 days.
Infobord.png More information
  • Plasma monitoring for TCA's is advisable, because of plasma-reponse relations, genetic polymorphism and under or overdosing.[3]
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. (dutch) monografie.org tricyclische-antidepressiva
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.